Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of Florida
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Stanford University
St. Jude Children's Research Hospital
Medical College of Wisconsin
Seattle Children's Hospital
Seattle Children's Hospital
Seattle Children's Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Baylor College of Medicine
Nationwide Children's Hospital
The University of Texas Health Science Center, Houston
Australian & New Zealand Children's Haematology/Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
University of California, San Francisco
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
University of Alabama at Birmingham
Emory University
City of Hope Medical Center
Mayo Clinic
Pediatric Brain Tumor Consortium
Ann & Robert H Lurie Children's Hospital of Chicago